Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Circulating mRNA signature as a marker for high-risk prostate cancer

Full text
Author(s):
de Souza, Marilesia Ferreira [1] ; Kuasne, Hellen [2] ; de Camargo Barros-Filho, Mateus [2] ; Ciliao, Heloisa Lizotti [1] ; Marchi, Fabio Albuquerque [2] ; Fuganti, Paulo Emilio [3] ; Rogatto, Silvia Regina [4] ; de Syllos Colus, Ilce Mara [1]
Total Authors: 8
Affiliation:
[1] Univ Estadual Londrina, Dept Gen Biol, Londrina, Parana - Brazil
[2] Int Res Ctr CIPE AC Camargo Canc Ctr, Sao Paulo, SP - Brazil
[3] Londrina Canc Hosp, Londrina, Parana - Brazil
[4] Univ Southern Denmark, Univ Hosp, Inst Reg Hlth Res, Dept Clin Genet, Vejle - Denmark
Total Affiliations: 4
Document type: Journal article
Source: Carcinogenesis; v. 41, n. 2, p. 139-145, FEB 2020.
Web of Science Citations: 0
Abstract

Prostate cancer (PCa) is the second most common cancer in men. The indolent course of the disease makes the treatment choice a challenge for physicians and patients. In this study, a minimally invasive method was used to evaluate the potential of molecular markers in identifying patients with aggressive disease. Cell-free plasma samples from 60 PCa patients collected before radical prostatectomy were used to evaluate the levels of expression of eight genes (AMACR, BCL2, NKX3-1, GOLM1, OR51E2, PCA3, SIM2 and TRPM8) by quantitative real-time PCR. Overexpression of AMACR, GOLM1, TRPM8 and NKX3-1 genes was significantly associated with aggressive disease characteristics, including extracapsular extension, tumor stage and vesicular seminal invasion. A trio of genes (GOLM1, NKX3-1 and TRPM8) was able to identify high-risk PCa cases (85% of sensitivity and 58% of specificity), yielding a better overall performance compared with the biopsy Gleason score and prostate-specific antigen, routinely used in the clinical practice. Although more studies are required, these circulating markers have the potential to be used as an additional test to improve the diagnosis and treatment decision of high-risk PCa patients. (AU)

FAPESP's process: 08/57887-9 - National Institute of Oncogenomics
Grantee:Luiz Paulo Kowalski
Support Opportunities: Research Projects - Thematic Grants